Switzerland's two pharma giants both just posted second-quarter beats. But they're navigating the same patent-cliff pressures from very different starting points, at different valuations, with different structures underneath them. Here's the detailed comparison — market cap, dividends, pipeline and all — before treating them as interchangeable "Swiss pharma" exposure.
Key takeaways
Two beats, one backdrop
Novartis and Roche both reported second-quarter 2026 results in the second half of July, and both came in ahead of what analysts had modelled. That's a useful data point on its own: Switzerland's two largest pharmaceutical companies, both perennial anchors of the SMI, delivering upside in the same quarter, against a backdrop where the index itself touched record highs in late June. But "both beat" is where the similarity mostly ends. The two companies are running genuinely different playbooks to get through the same industry-wide problem — patent expiries on the blockbuster drugs that built their current revenue base — and that difference shows up in almost every number that matters: size, valuation, income profile and business mix.
Novartis: the lean, focused bet
Since spinning off its generics arm, Sandoz, in 2023, Novartis has positioned itself as a pure-play innovative-medicines company, concentrated on oncology, immunology, cardiovascular and neuroscience. That focus was visible in the Q2 numbers: growth from newer launches — the breast cancer drug Kisqali and the psoriasis treatment Cosentyx among them — helped offset the ongoing decline of Entresto, the heart-failure drug now facing patent-cliff erosion after years as one of the company's largest sellers. Management reaffirmed full-year guidance alongside the results. On the numbers: Novartis currently trades around a market capitalisation in the region of $290–310 billion, at a price-to-earnings ratio broadly in the mid-to-high teens, with a dividend yield close to 3% — and a dividend that has not been cut in 25 consecutive years, a streak that matters more to income-focused holders than the headline yield alone. CEO Vas Narasimhan has framed the story as one of successfully replacing a maturing blockbuster with a broader base of newer drugs before the patent cliff bites too hard — Q2 was the first quarter in a while where that replacement math clearly worked in Novartis's favour.
Roche: the diversified giant
Roche is playing a different hand, and starts from a different scale entirely: at a market capitalisation in the region of $350–370 billion, it is larger than Novartis by a comfortable margin and currently ranks as the single largest company in the SMI by market value, with Novartis in second place. Alongside its pharmaceuticals business, Roche holds a large diagnostics division — a structural difference from Novartis that gives it a second, less patent-sensitive revenue stream and roughly a third more in annual revenue than its cross-town rival. On the pharma side, Q2 operating profit rose by roughly 10%, with the multiple sclerosis treatment Ocrevus standing out as a major contributor. Roche is also one of Europe's most reliable dividend growers, with an increase streak stretching back decades — a profile that tends to appeal to a different kind of holder than a company still proving out a post-patent-cliff growth story. Where Novartis's Q2 story was about newer drugs outrunning an old one, Roche's was closer to steady execution across an already-diversified base.
Head to head: the numbers
| Metric | Novartis | Roche |
|---|---|---|
| SMI ranking | 2nd largest | Largest |
| Market capitalisation | ~$290–310bn | ~$350–370bn |
| Approx. annual revenue | ~$50–55bn | ~$65–70bn |
| Dividend yield | ~3% | Lower headline yield, longer growth streak |
| Dividend track record | 25 years without a cut | Multi-decade streak of increases |
| Business structure | Pure-play innovative medicines (post-Sandoz spin-off) | Pharmaceuticals + Diagnostics |
| Q2 2026 result | Beat expectations; guidance reaffirmed | Beat expectations; operating profit +~10% |
| Q2 growth driver | Kisqali, Cosentyx offsetting Entresto decline | Ocrevus (multiple sclerosis) |
The picture that emerges is less "which is the better stock" than "which role each plays in a portfolio." Novartis is the leaner, more concentrated vehicle — smaller, cheaper on some multiples, and more directly geared to whether its newer drugs keep outrunning what's coming off patent. Roche is the larger, more diversified holding, with diagnostics providing a buffer Novartis no longer has since the Sandoz spin-off, and a dividend history that skews toward long-term income investors.
The shared challenge: pricing and patents
Both companies raised list prices on dozens of prescription drugs at the start of 2026 — Novartis on around 48, including an 8% increase on the multiple sclerosis drug Kesimpta, and Roche on around 27, including increases on Ocrevus and the asthma treatment Xolair. Price increases of that scale, repeated year after year, are as much a signal as a revenue lever: they point to an industry still leaning on pricing power in its most established products while newer pipelines take shape. Patent cliffs are not a Novartis-specific or Roche-specific story; they're the defining feature of large-cap pharma this decade, and both companies are managing the same underlying pressure from different starting positions and different balance-sheet cushions.
Where the pipelines diverge
Novartis's pipeline is concentrated where its post-Sandoz strategy points: oncology (including its radioligand-therapy platform), immunology, cardiovascular disease and neuroscience, with Kisqali and Cosentyx as the current proof points that newer drugs can scale fast enough to matter. Roche's pipeline is broader by design, spanning oncology, immunology, neuroscience and — increasingly — the metabolic and obesity space that Novo Nordisk and Eli Lilly have made the industry's most closely watched category; Roche's diagnostics arm also gives it a distinct, data-driven view into disease trends that a pure pharma player doesn't have in the same way. Neither company's pipeline bet is proven out yet — that's true of every large pharma name navigating this decade — but the shape of the bet is genuinely different, which is the main reason lumping the two together as generic "Swiss pharma" exposure understates how differently they'd behave in, say, a scenario where oncology pricing comes under political pressure, or where obesity-drug competition intensifies faster than expected.
Two routes, same portfolio?
For a diversified Swiss equity allocation, the two aren't simple substitutes for one another. Novartis is the more concentrated bet on innovative-medicines execution, smaller and somewhat cheaper on a multiples basis, with a strategy that depends on the pipeline continuing to outrun what's coming off patent. Roche is the larger, more diversified holding, with diagnostics providing ballast that Novartis, since the Sandoz spin-off, no longer has, and a dividend history that tilts it toward long-term income portfolios. Both sit near the top of the SMI, both are exposed to the same sector-wide patent-cliff dynamics, and both just showed they can deliver a beat under that pressure — which is less a reason to pick one over the other than the reason many diversified Swiss portfolios end up holding some of both.
Bottom line
"Novartis vs. Roche" is really a false choice for most diversified portfolios — the more useful question is what each contributes. Novartis offers a leaner, more concentrated read on whether newer drugs can keep outrunning patent expiries; Roche offers scale, diagnostics diversification and one of the market's longer dividend-growth track records. Both delivered this quarter. The patent-cliff pressure that shapes both of their next few years isn't going away — which is exactly why the difference in how each company is built matters more than the shared "beat expectations" headline suggests.
